Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Zimmer Holdings



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 1.0%. By the end of trading, Zimmer Holdings rose $0.93 (1.0%) to $93.97 on average volume. Throughout the day, 1,460,274 shares of Zimmer Holdings exchanged hands as compared to its average daily volume of 1,080,200 shares. The stock ranged in a price between $92.50-$94.42 after having opened the day at $93.22 as compared to the previous trading day's close of $93.04. Other companies within the Health Care sector that increased today were:




), up 15.3%,

Enanta Pharmaceuticals



), up 13.4%,

Idera Pharmaceuticals



TheStreet Recommends

), up 12.6% and

Arrhythmia Research Technology



), up 9.1%.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. Zimmer Holdings has a market cap of $16.0 billion and is part of the health services industry. The company has a P/E ratio of 24.4, above the S&P 500 P/E ratio of 17.7. Shares are up 3.7% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Zimmer Holdings a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates

Zimmer Holdings

as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front,




), down 17.9%,




), down 13.5%,

CytRx Corporation



), down 13.0% and

Oramed Pharmaceuticals



), down 11.4% , were all laggards within the health care sector with

Celgene Corporation



) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.